KAPA

Kairos Pharma, LTD.

Healthcare · Biotechnology

$57.78 sample

-0.71 (-1.21%) 1D

Market cap

$133.5B

Price as of

2026-10-15

Latest filing

8-K · 2026-10-06

Alerts

8

Price$57.78 -3.13% 3M daily closessample

64.3757.78

2026-07-202026-08-112026-09-022026-09-232026-10-15

purchase / approvalsale / rejectionfiling / neutral

Latest events

Filings, trades, FDA; newest first

Oct 06SECDEF 14A filed
Sep 25INSInsider buy: General Counsel
Sep 16INSInsider buy: 10% owner
Sep 10INSInsider sell: 10% owner
Sep 07SEC8-K filed: material event
Aug 28INSInsider sell: EVP, Operations
Aug 25SECDEF 14A filed
Aug 19INSInsider sell: Chief Financial Officer

Sign up to see the real KAPA record →

Company facts

SEC EDGAR registration

Name: Kairos Pharma, LTD.
Sector: Healthcare
Industry: Biotechnology
Smart-money score: -38sample, -100 to +100
Reporting currency: USD

Who is positioning in KAPA

sample

Insiders: 18 insider transactions over 90 days, net selling, $194.5M
Congress: 5 members traded over 90 days
Institutions · 13F: 34 funds hold $1.9B
Activists · 13D/G: No 13D/13G activist filings on record

How are the fundamentals trending?

sample, by period end

Revenue$6.5B +17.9% y/y

Q4 2024Q3 2026

Inventory$3.9B +13.6% y/y

Q4 2024Q3 2026

Accounts receivable$2.8B +8.7% y/y

Q4 2024Q3 2026

Total debt$7.8B +18.0% y/y

Q4 2024Q3 2026

Peers

sample

Sample peer A: $70.2B -2.9% 3M
Sample peer B: $111.1B +1.3% 3M
Sample peer C: $66.9B -0.9% 3M
Sample peer D: $131.1B +6.8% 3M
Sample peer E: $26.2B -11.1% 3M